Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

Preclinical and clinical data demonstrate that neutralizing GDF-15 with visugromab effectively alleviates cancer-induced cachexia, characterized by severe weight and muscle mass loss Patients with ...

EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”, the “Company”) an innovative clinical-stage biotechnology company focused on developing transformative treatments for chronic inflammatory ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

Janowitz's essay not only points to new potential therapeutic strategies for cancer cachexia and other diseases. It calls for closer collaboration between cancer researchers and neuroscientists.

Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

Cancer ravages both body and mind. If you've ever lost loved ones to the disease, you might recognize the physical and emotional changes cancer patients often endure during their final months. They ...

Tumor growth is associated with profound metabolic and neurochemical alterations, which can lead to the onset of anorexia−cachexia syndrome. Anorexia is defined as the loss of the desire to eat, while ...

In cachexia, liver metabolism is fundamentally reprogrammed. One gene, which normally regulates the liver’s activity throughout the day, ceases to function properly. Using a mouse model, the ...

The dietary supplement melatonin does not improve the symptoms of cachexia in patients with advanced cancer, according to a study published online February 25 in the Journal of Clinical Oncology.

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...